NCT04459338View on ClinicalTrials.gov

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

June 14, 2022

Study Completion Date

June 14, 2022

Conditions
Healthy
Interventions
BIOLOGICAL

Exendin-9,39

Exendin-9,39 is a competitive antagonist of GLP-1 actions at the GLP-1 receptor

OTHER

Saline

Placebo comparator

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Adrian Vella

OTHER

NCT04459338 - A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion | Biotech Hunter | Biotech Hunter